Research programme: erectile dysfunction therapies - Sagene Pharmaceuticals

Drug Profile

Research programme: erectile dysfunction therapies - Sagene Pharmaceuticals

Alternative Names: Selegiline/phosphodiesterase-5 inhibitor; SPI-1972

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sagene Pharmaceuticals
  • Class Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Erectile dysfunction

Most Recent Events

  • 28 Feb 2018 Preclinical development for erectile dysfunction therapies is ongoing in USA (Sagene Pharmaceuticals pipeline, February 2018)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA (PO)
  • 12 Sep 2011 Preclinical trials in Erectile dysfunction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top